“I didn’t start this journey in a lab. I started with questions; about family, resilience and why some people seem naturally protected from disease. That search turned into Lyara Therapeutics.”
- Sara L
Sara Liyanage
Founder & CEO
Lyara Therapeutics
Sara Liyanage is the Founder and Genetic Discovery lead of Lyara Therapeutics, a biotechnology platform focused on identifying and developing rare genetic variants with therapeutic and resilience-associated potential.
Her work began through independent genomic analysis, where she identified patterns in protective and low-frequency variants associated with disease resistance, immune function and cognitive resilience. These early discoveries established the foundation for Lyara's platform; systematic identification, validation and protection of rare genetic architecture with translational potential.
Prior to formally establishing Lyara Pty Ltd in 2026, Sara's findings attracted scientific interest and external validation, reinforcing the potential of rare variant focused discovery as an emerging frontier in biotechnology. This validation catalyzed the transition from independent research into a formalized platform structure.
Today, Lyara Therapeutics operates as a discovery and licensing platform that is focussed on advancing rare genetic targets relevant to neuroprotection, immune resilience, radiation resilience and age-related disease pathways. The platform is designed to support downstream therapeutic development through strategic partnerships, validation pathways and licensing opportunities.
Sara leads Lyara with a focus on scientific integrity, long-term platform value and the belief that genetic variation represents one of the most underexplored frontiers in modern medicine.